| Literature DB >> 34173807 |
Khalil Charafeddine1, Patrick Zakka2, Bassel Bou Dargham3, Farah Abdulhai4, Katerina Zakka5, Fouad A Zouein6, Marwan Refaat4.
Abstract
ABSTRACT: In risk-stratifying patients with atrial fibrillation (AF), physicians rely heavily on clinical parameters that provide risk scores and determine treatment strategies. There has been increasing research on potential biomarkers in the blood that could more accurately determine both risk of complications in AF and risk of incidence of AF. This review highlights the clinical significance of 5 novel biomarkers that have been shown to be linked to AF. These biomarkers are carbohydrate antigen 125, galectin-3, growth differentiation factor-15, a member of the interleukin 1 receptor family, IL1RL1 (ST2), and N-terminal pro B-type natriuretic peptide.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34173807 DOI： 10.1097/FJC.0000000000001042
Source DB: PubMed Journal: J Cardiovasc Pharmacol ISSN： 0160-2446 Impact factor: 3.105